Acambis to announce third quarter results on 25 November 2003

Cambridge, UK and Cambridge, Massachusetts - 11 November 2003 - Acambis plc
("Acambis") (LSE: ACM, NASDAQ: ACAM) will announce its results for the third
quarter ended 30 September 2003 on Tuesday, 25 November.

The results announcement will be released at 7.00 am GMT. A conference call for
analysts will be held at 9.30 am GMT. For details, contact Mo Noonan at
Financial Dynamics on telephone number +44 (0) 20 7269 7116. An instant replay
of the call will be available until 24 December 2003 on telephone number UK:
+44 (0) 20 8288 4459 and US: +1 334 323 6222. The pin code is 114342.

An audio webcast of the call will also be available via Acambis' website at
www.acambis.com. The webcast replay will be available until Wednesday, 25
February 2004.

                                    -ends-                                     

Enquiries:

Acambis plc                                                                    
                                                                               
Lyndsay Wright, Director of                                                    
Communications                                                                 
                                                                               
Tel: +44 (0) 1223 275 300                                                      
                                                                               
Financial Dynamics                                                             
                                                                               
Mo Noonan                                                                      
                                                                               
Tel: +44 (0) 20 7831 3113                                                      

Notes to editors:

Acambis is a leading developer of vaccines to prevent and treat infectious
diseases. Recognised internationally as the leading producer of smallpox
vaccines, Acambis is developing a second-generation smallpox vaccine which is
currently undergoing clinical trials and, under a unique arrangement given the
threat of smallpox being used as a bioterrorist weapon, is manufacturing
emergency-use stockpiles of this investigational vaccine for the US Government
and other governments around the world. Acambis is establishing a travel
vaccines franchise through its US-based subsidiary Berna Products Corporation,
which markets Vivotif�, the world's only oral typhoid vaccine, in North
America. Acambis has a number of other potential travel vaccines in development
and is conducting clinical trials of vaccines against yellow fever, Japanese
encephalitis and dengue fever. Acambis is also preparing to start clinical
trials of a vaccine targeting the West Nile virus, which has spread to 45 US
States in the last four years.

Acambis is based in Cambridge, UK and Cambridge, Massachusetts, US. Its primary
listing is on the London Stock Exchange (ACM) and its shares are listed in the
form of American Depositary Receipts on Nasdaq (ACAM). More information is
available at www.acambis.com.



END